


Developed by



Supported by



Bedaquiline

Developer(s)




Janssen Pharmaceuticals

<https://www.janssen.com>

Belgium

Janssen Pharmaceuticals is a subsidiary company of Johnson & Johnson headquartered in Beerse, Belgium. They focus on manufacturing and developing pharmaceutical products for use in areas such as, Immunology, Infectious Diseases & Vaccines, Pulmonary Hypertension, Cardiovascular & Metabolism, Oncology, and Neuroscience.

Drug structure



Bedaquiline Structure

Sourced from DrugBank

Drug information

Associated long-acting platforms

Polymer-based particles, In-situ forming gel/implant, Based on other organic particles

Administration route

Oral, Intramuscular, Subcutaneous, Intravenous

Therapeutic area(s)

TB

Use case(s)

Treatment

Use of drug

Ease of administration

Administered by a nurse

Administered by a specialty health worker

User acceptance

Not provided

Dosage

Available dose and strength

long acting formulation is being investigated

Frequency of administration

Not provided

Maximum dose

Not provided

Recommended dosing regimen

Not provided

Additional comments

Not provided

Dosage link(s)

Not provided

Drug information

Drug's link(s)

Not provided

Generic name

Bedaquiline

Brand name

Sirturo

Compound type

Small molecule

Summary

Bedaquiline (BDQ), also known as TMC207, is a diarylquinoline used for the treatment of pulmonary multidrug-resistant Mycobacterium tuberculosis (MDR-TB) as part of multifactorial treatment regimen in adult patients. BDQ inhibits mycobacterial F1F0-ATP synthase in a species-specific manner and displays potent bactericidal activity against both susceptible and MDR strains of TB. Due to possible serious adverse effects, the prescribing of BDQ requires close monitoring by experts in MDR-TB management, as its use is not recommended for all patients. BDQ is postulated to have suitable profile for long-acting injectable formulation, as it has an extended half-life (164 days), high lipophilicity (logP 7.25) and displays a low M. tuberculosis specific minimum inhibitory concentration (~0.03µg/ml).

Approval status

Unknown

Regulatory authorities

Unknown

Delivery device(s)

No delivery device

Scale-up and manufacturing prospects

Scale-up prospects

Formulations for long-acting Bedaquiline are currently in pre-clinical development, and therefore detailed scale-up information is unavailable. Several promising long-acting formulation approaches have been reported, including: (1) nanoemulsion-based chitosan nanocapsules, (2) lipid nanoparticles, and (3) a PLGA in-situ forming gel.

Tentative equipment list for manufacturing

Detailed information regarding industrial manufacturing requirements and/or equipment lists is currently not available as long-acting bedaquiline formulations have only been produced at small-scale for preclinical research use.

Manufacturing

Not provided

Specific analytical instrument required for characterization of formulation

Not provided

Clinical trials

A Single Ascending Dose, Single-Centre Study, to Assess Pharmacokinetics, Safety and Tolerability of a Single Intramuscular Dose of Bedaquiline Long-Acting Injection Formulation in Healthy Participants

Identifier

EUCT 2023-508810-41-00

Link

<https://euclinicaltrials.eu/ctis-public/view/2023-508810-41-00?lang=en>

Phase

Phase I

Status

Recruiting

Sponsor

Janssen Cilag International

More details

Not provided

Purpose

Safety and Tolerability of a Single Intramuscular Dose of Bedaquiline Long-Acting Injection Formulation

Interventions

Intervention 1

Single Intramuscular Dose of Bedaquiline Long-Acting Injection Formulation

Countries

Austria

Sites / Institutions

Not provided

Trials dates

Anticipated Start Date

2024-06-03

Actual Start Date

2024-07-02

Anticipated Date of Last Follow-up

Not provided

Estimated Primary Completion Date

Not provided

Estimated Completion Date

2026-02-17

Actual Primary Completion Date

Not provided

Actual Completion Date

Not provided

Studied populations

Age Cohort

- Adults

Genders

- All

Accepts pregnant individuals

Unspecified

Accepts lactating individuals

Unspecified

Accepts healthy individuals

Yes

Comments about the studied populations

study protocol code: TMC207TBC1006

Health status

Negative to : TB

Study type

Interventional (clinical trial)

Enrollment

Not provided

Allocation

Non-randomized

Intervention model

Not provided

Intervention model description

Not provided

Masking

Open label

Masking description

Not provided

Frequency of administration

Other(s) : "unknown "

Studied LA-formulation(s)

Injectable

Studied route(s) of administration

To be determined

Use case

Treatment

Key results

Not provided

Excipients

Proprietary excipients used

Not provided

Novel excipients or existing excipients at a concentration above Inactive Ingredients Database (IID) for the specified route of administration

Not provided

Residual solvents used

Not provided

Patent info

Compound patent families

Patent informations

Patent description	Representative patent	Categories	Patent holder	Licence with MPP	Patent source
<p>Bedaquiline Long-acting formulations (suspension of micro- or nanoparticles)</p> <p>Expiry date: 2038-07-13</p> <p>This invention concerns pharmaceutical compositions for administration via intramuscular or subcutaneous injection, comprising micro- or nanoparticles of the anti-TB compound bedaquiline, suspended in an aqueous pharmaceutically acceptable carrier, and the use of such pharmaceutical compositions in the treatment and prophylaxis of a pathogenic mycobacterial infection.</p>	WO2019012100	Composition	Janssen Pharmaceutica Nv	No	

Patent status

Patent status/countries	Low, Low- middle and upper-middle	High income
Granted	<p>China, Kazakhstan, Morocco, Tunisia, Albania, Serbia, Bosnia and Herzegovina, Cambodia, Montenegro, Türkiye, Moldova, Republic of, North Macedonia, Jordan, Peru, Ukraine, South Africa, Sierra Leone, Eswatini, Liberia, Namibia, Sao Tome and Principe, Mozambique, Uganda, Zambia, Zimbabwe, Tanzania, United Republic of, Malawi, Ghana, Sudan, Botswana, Lesotho, Kenya, Gambia (the), Indonesia, Mexico, Nigeria, Congo, Mauritania, Guinea-Bissau, Niger, Senegal, Cameroon, Mali, Togo, Burkina Faso, Benin, Côte d'Ivoire, Central African Republic, Comoros, Guinea, Gabon, Equatorial Guinea, Chad, Viet Nam</p>	<p>Australia, Russian Federation, Liechtenstein, Italy, Norway, Malta, Denmark, Belgium, United Kingdom, Greece, Netherlands, Hungary, Croatia, Switzerland, Spain, San Marino, Slovenia, Austria, Romania, Iceland, Cyprus, Finland, France, Bulgaria, Slovakia, Poland, Latvia, Ireland, Estonia, Germany, Luxembourg, Portugal, Czechia, Lithuania, Monaco, Sweden, Japan, Korea, Republic of, Saudi Arabia, United States of America, Hong Kong</p>

Patent status/countries	Low, Low- middle and upper-middle	High income
Filed	Brazil, China, Albania, Serbia, Türkiye, North Macedonia, Philippines, Papua New Guinea, Thailand, Uzbekistan	Canada, Liechtenstein, Italy, Norway, Malta, Denmark, Belgium, United Kingdom, Greece, Netherlands, Hungary, Croatia, Switzerland, Spain, San Marino, Slovenia, Austria, Romania, Iceland, Cyprus, Finland, France, Bulgaria, Slovakia, Poland, Latvia, Ireland, Estonia, Germany, Luxembourg, Portugal, Czechia, Lithuania, Monaco, Sweden, Kuwait, Qatar
Not in force	World Intellectual Property Organization (WIPO), Colombia, Tajikistan, Belarus, Azerbaijan, Turkmenistan, Armenia, Kyrgyzstan, Morocco, Tunisia, Bosnia and Herzegovina, Cambodia, Montenegro, Moldova, Republic of, India, Rwanda	World Intellectual Property Organization (WIPO), Korea, Republic of

Patent informations

Patent description	Representative patent	Categories	Patent holder	Licence with MPP	Patent source
Bedaquiline fumarate salt and solid compositions Expiry date: 2027-12-03 Bedaquiline fumarate salt, pharmaceutical compositions comprising as active ingredient said salt and to processes for their preparation.	WO2008068231	Salt	Aelterman, Wim, Albert, Alex, Faure, Anne, Hegyi, Jean Francois, Alexandre, Lucas, Janssen Pharmaceutica N.V, Lang, Yolande, Lydia, Leys, Carina, Stokbroekx, Sigrid, Carl, Maria, Van Remoortere, Peter, Jozef, Maria	No	

Patent status

Patent status/countries	Low, Low- middle and upper-middle	High income
Granted	Türkiye, Botswana, Gambia (the), Ghana, Kenya, Lesotho, Malawi, Mozambique, Namibia, Sierra Leone, Sudan, Eswatini, Tanzania, United Republic of, Uganda, Zambia, Zimbabwe, Turkmenistan, Belarus, Tajikistan, Kazakhstan, Azerbaijan, Kyrgyzstan, Armenia, Moldova, Republic of, Mexico, Peru, South Africa, Lebanon, Indonesia, Jordan, Montenegro, Philippines, Viet Nam, Kosovo, Sri Lanka, Benin, Cameroon, Burkina Faso, Chad, Guinea-Bissau, Mali, Senegal, Congo, Guinea, Gabon, Niger, Equatorial Guinea, Mauritania, Togo, Côte d'Ivoire, Central African Republic, Serbia, North Macedonia, Bosnia and Herzegovina, Albania	United States of America, Australia, Canada, Belgium, Germany, France, Luxembourg, Netherlands, Switzerland, United Kingdom, Sweden, Italy, Austria, Liechtenstein, Greece, Spain, Denmark, Monaco, Portugal, Ireland, Finland, Cyprus, Bulgaria, Czechia, Estonia, Slovakia, Slovenia, Hungary, Romania, Poland, Iceland, Lithuania, Latvia, Malta, Hong Kong, Japan, Korea, Republic of, Norway, New Zealand, Taiwan, Province of China, Chile, Russian Federation, Uruguay, Bahrain, Kuwait, Qatar, Saudi Arabia, Oman, United Arab Emirates, Israel, Brunei Darussalam, Panama, Singapore, Croatia
Filed	Venezuela (Bolivarian Republic of), Pakistan	

Patent status/countries**Low, Low- middle and upper-middle****High income**

Not in force

Argentina, Brazil, China, Malaysia, India,
World Intellectual Property Organization
(WIPO), Ukraine, Thailand, EgyptJapan, World Intellectual Property
Organization (WIPO)

Patent informations

Patent description	Representative patent	Categories	Patent holder	Licence with MPP	Patent source
Bedaquiline to treat latent TB Expiry date: 2025-12-08 Use of bedaquiline for the manufacture of a medicament for the treatment of latent tuberculosis	WO2006067048	Use	Janssen Pharmaceutica N.V	No	

Patent status

Patent status/countries	Low, Low- middle and upper-middle	High income
Granted	Botswana, Gambia (the), Ghana, Kenya, Lesotho, Malawi, Mozambique, Namibia, Sierra Leone, Sudan, Eswatini, Tanzania, United Republic of, Uganda, Zambia, Zimbabwe, Brazil, China, Jordan, Ukraine, South Africa, Montenegro, Indonesia, Sri Lanka, Mexico, Benin, Cameroon, Burkina Faso, Chad, Guinea-Bissau, Mali, Senegal, Congo, Guinea, Gabon, Niger, Equatorial Guinea, Mauritania, Togo, Côte d'Ivoire, Central African Republic, Pakistan, Albania, Bosnia and Herzegovina, North Macedonia	Canada, Australia, Bulgaria, Cyprus, Germany, Denmark, Belgium, France, Luxembourg, Netherlands, Switzerland, United Kingdom, Sweden, Italy, Austria, Liechtenstein, Greece, Spain, Monaco, Portugal, Ireland, Finland, Czechia, Estonia, Slovakia, Slovenia, Hungary, Romania, Poland, Iceland, Lithuania, Latvia, Hong Kong, Croatia, Israel, Japan, Korea, Republic of, Norway, New Zealand, Taiwan, Province of China, Panama, Bahrain, Kuwait, Qatar, Saudi Arabia, Oman, United Arab Emirates, Macao, Malta, Singapore, Trinidad and Tobago
Filed	Nicaragua, Kosovo, Lebanon, Thailand, Venezuela (Bolivarian Republic of)	Cyprus, Germany, Denmark, Spain, Portugal, Slovenia, Poland, Japan
Not in force	Türkiye, Argentina, China, Costa Rica, Turkmenistan, Belarus, Tajikistan, Kazakhstan, Azerbaijan, Kyrgyzstan, Armenia, Moldova, Republic of, Malaysia, Serbia, India, World Intellectual Property Organization (WIPO), Ecuador, Egypt, Philippines, Viet Nam	Bulgaria, Estonia, Latvia, Japan, Korea, Republic of, United States of America, Russian Federation, World Intellectual Property Organization (WIPO)

Patent informations

Patent description	Representative patent	Categories	Patent holder	Licence with MPP	Patent source
<p>Bedaquiline to treat MDR TB and/or combinations with other antimycobacterial agents</p> <p>Expiry date: 2025-05-24</p> <p>The invention relates to the use of a substituted quinoline derivative for the preparation of a medicament for the treatment of an infection with a drug resistant Mycobacterium strain wherein the substituted quinoline derivative is a compound according to Formula (Ia) or Formula (Ib) the pharmaceutically acceptable acid or base addition salts thereof, the stereochemically isomeric forms thereof, the tautomeric forms thereof and the N-oxide forms thereof. Also claimed is a composition comprising a pharmaceutically acceptable carrier and, as active ingredient, a therapeutically effective amount of the above compounds and one or more other antimycobacterial agents.</p>	WO2005117875	Use	Janssen Pharmaceutica N.V	No	

Patent status

Patent status/countries	Low, Low- middle and upper-middle	High income
-------------------------	-----------------------------------	-------------

Granted	Türkiye, Brazil, China, Turkmenistan, Belarus, Tajikistan, Kazakhstan, Azerbaijan, Kyrgyzstan, Armenia, Moldova, Republic of, Mexico, Malaysia, Serbia, Ukraine, South Africa, India, Indonesia, Kosovo, Lebanon, Benin, Cameroon, Burkina Faso, Chad, Guinea-Bissau, Mali, Senegal, Congo, Guinea, Gabon, Niger, Equatorial Guinea, Mauritania, Togo, Côte d'Ivoire, Central African Republic, Philippines, Venezuela (Bolivarian Republic of), Viet Nam, Montenegro, Jordan, Albania, North Macedonia	Canada, Australia, Germany, Belgium, France, Luxembourg, Netherlands, Switzerland, United Kingdom, Sweden, Italy, Austria, Liechtenstein, Greece, Spain, Denmark, Monaco, Portugal, Ireland, Finland, Cyprus, Czechia, Estonia, Slovakia, Slovenia, Hungary, Romania, Poland, Iceland, Lithuania, Hong Kong, Israel, Japan, Korea, Republic of, Norway, New Zealand, Taiwan, Province of China, Russian Federation, Panama, Bahrain, Kuwait, Qatar, Saudi Arabia, Oman, United Arab Emirates, Croatia, Latvia, Macao
Filed	Pakistan, Thailand, Egypt	
Not in force	World Intellectual Property Organization (WIPO), Botswana, Gambia (the), Ghana, Kenya, Lesotho, Malawi, Mozambique, Namibia, Sierra Leone, Sudan, Eswatini, Tanzania, United Republic of, Uganda, Zambia, Zimbabwe, Argentina, China, Sri Lanka, Bosnia and Herzegovina	Bulgaria, Korea, Republic of, United States of America, World Intellectual Property Organization (WIPO), Chile

Patent informations

Patent description	Representative patent	Categories	Patent holder	Licence with MPP	Patent source
<p>Bedaquiline compounds</p> <p>Expiry date: 2023-07-18</p> <p>Novel compounds, in particular substituted quinoline derivatives, having the property of inhibiting growth of mycobacteria and therefore useful for the treatment of mycobacterial diseases, particularly those diseases caused by pathogenic mycobacteria such as Mycobacterium tuberculosis, M. bovis, M. avium and M. marinum.</p>	WO2004011436	Compound	Janssen Pharmaceutica N.V	No	

Patent status

Patent status/countries	Low, Low- middle and upper-middle	High income
Granted	Montenegro, Ukraine, Sri Lanka	United States of America, Belgium, Germany, France, Luxembourg, Netherlands, United Kingdom, Sweden, Italy, Austria, Greece, Denmark, Finland, Cyprus, Bulgaria, Estonia, Slovakia, Hungary, Romania, Russian Federation, Israel, Iceland, Japan, Korea, Republic of, Norway, Poland, Taiwan, Province of China, Chile, Latvia, Lithuania, Malta, Singapore
Filed		Cyprus

Patent status/countries**Low, Low- middle and upper-middle****High income**

Not in force

Türkiye, Argentina, Brazil, China, Turkmenistan, Belarus, Tajikistan, Kazakhstan, Azerbaijan, Kyrgyzstan, Armenia, Moldova, Republic of, World Intellectual Property Organization (WIPO), Mexico, Malaysia, Yugoslavia/Serbia and Montenegro, South Africa, India, Bosnia and Herzegovina, Egypt, Indonesia, Kosovo, Benin, Cameroon, Burkina Faso, Chad, Guinea-Bissau, Mali, Senegal, Congo, Guinea, Gabon, Niger, Equatorial Guinea, Mauritania, Togo, Côte d'Ivoire, Central African Republic, Pakistan, Philippines, Thailand, Viet Nam, Botswana, Gambia (the), Ghana, Kenya, Lesotho, Malawi, Mozambique, Sierra Leone, Sudan, Eswatini, Tanzania, United Republic of, Uganda, Zambia, Zimbabwe, Albania, North Macedonia

Australia, Canada, Belgium, Germany, France, Luxembourg, Netherlands, Switzerland, United Kingdom, Sweden, Italy, Austria, Liechtenstein, Greece, Spain, Denmark, Monaco, Portugal, Ireland, Finland, Cyprus, Bulgaria, Czechia, Estonia, Slovakia, Slovenia, Hungary, Romania, Hong Kong, Croatia, New Zealand, World Intellectual Property Organization (WIPO), Bahrain, Kuwait, Qatar, Saudi Arabia, Oman, United Arab Emirates, Latvia, Lithuania

Supporting material

Publications

L. De Matteis, D. Jary, A. Lucía, S. García-Embid, I. Serrano-Sevilla, D. Pérez, J.A. Ainsa, F.P. Navarro, J. M. de la Fuente, New active formulations against *M. tuberculosis*: Bedaquiline encapsulation in lipid nanoparticles and chitosan nanocapsules, *Chemical Engineering Journal*, Volume 340, 2018, Pages 181-191, ISSN 1385-8947, <https://doi.org/10.1016/j.cej.2017.12.110>.

In the last years, the increase in antimicrobial resistance, together with a lack of new drugs for the treatment of bacterial infections resistant to classical antibiotics are of growing concern. Moreover, some of current therapies induce severe side effects and are often difficult to administer. In 2012 the FDA approved the use of bedaquiline, as the first new very effective drug against TB in the last 40 years. Despite its effectiveness, unfortunately bedaquiline side effects can be so dangerous that at present it is to be prescribed only when no other treatment options are available. The development of effective and safe nanotechnology-based methods can be particularly relevant to increase antimicrobial concentration at the site of infection, to reduce doses in the general circulation, which in turn reduces adverse effects. In this work bedaquiline was encapsulated in two types of nanocarriers, lipid nanoparticles and chitosan-based nanocapsules with high encapsulation efficiency and drug loading values. The efficacy of the drug-encapsulating nanocarriers has been demonstrated *in vitro* against *Mycobacterium tuberculosis*, together with the excellent compatibility of both carriers with animal cells. The obtained results open the way for further studies on multi-drug resistant strains of *M. tuberculosis* and for *in vivo* studies of the optimized nanocarriers. The promising behaviour of drug-loaded nanocarriers will hopefully lead to a reduction of the administered doses of a quite dangerous drug as bedaquiline, tuning its biodistribution and so decreasing its adverse effects, finally allowing its use in a higher number of patients.

Kaushik A, Ammerman NC, Tyagi S, Saini V, Vervoort I, Lachau-Durand S, Nuermberger E, Andries K. Activity of a Long-Acting Injectable Bedaquiline Formulation in a

Paucibacillary Mouse Model of Latent Tuberculosis Infection. *Antimicrob Agents Chemother.* 2019 Mar 27;63(4):e00007-19. DOI: 10.1128/AAC.00007-19. PMID: 30745396; PMCID: PMC6437534.

The potent antituberculosis activity and long half-life of bedaquiline make it an attractive candidate for use in long-acting/extended-release formulations for the treatment of latent tuberculosis infection (LTBI). Our objective was to evaluate a long-acting injectable (LAI) bedaquiline formulation in a validated paucibacillary mouse model of LTBI. Following immunization with *Mycobacterium bovis* rBCG30, BALB/c mice were challenged by aerosol infection with *M. tuberculosis* H37Rv. Treatment began 13 weeks after challenge infection with one of the following regimens: an untreated negative-control regimen; positive-control regimens of daily rifampin (10 mg/kg of body weight), once-weekly rifapentine (15 mg/kg) and isoniazid (50 mg/kg), or daily bedaquiline (25 mg/kg); test regimens of one, two, or three monthly doses of LAI bedaquiline at 160 mg/dose (BLAI-160); and test regimens of daily bedaquiline at 2.67 mg/kg (B2.67), 5.33 mg/kg (B5.33), or 8 mg/kg (B8) to deliver the same total amount of bedaquiline as one, two, or three doses of BLAI-160, respectively. All drugs were administered orally, except for BLAI-160 (intramuscular injection). The primary outcome was the decline in *M. tuberculosis* lung CFU counts during 12 weeks of treatment. The negative- and positive-control regimens performed as expected. One, two, and three doses of BLAI-160 resulted in decreases of 2.9, 3.2, and 3.5 log₁₀ CFU/lung, respectively, by week 12. Daily oral dosing with B2.67, B5.33, and B8 decreased lung CFU counts by 1.6, 2.8, and 4.1 log₁₀, respectively. One dose of BLAI-160 exhibited activity for at least 12 weeks. The sustained activity of BLAI-160 indicates that it shows promise as a short-course LTBI treatment requiring few patient encounters to ensure treatment completion.

Van Hemelryck S, Wens R, van Poppel H, Luijks M, Shahidi K, Marczak M, Kahnt A, Holm R, Mannaert E, Langguth P. In Vitro Evaluation of Poly(lactide-co-glycolide) In Situ Forming Gels for Bedaquiline Fumarate Salt and Pharmacokinetics Following Subcutaneous Injection in Rats. *Pharmaceutics.* 2021 Aug 10;13(8):1231. DOI: 10.3390/pharmaceutics13081231. PMID: 34452192; PMCID: PMC8400137.

This study evaluated *in vitro* and *in vivo* drug release of bedaquiline from *in situ* forming gels (ISGs) containing 200 mg eq./g bedaquiline fumarate salt prepared with four different grades of poly(D,L-lactide) (PDLLA) or poly(D,L-lactide-co-glycolide) (PLGA) with a lactide/glycolide ratio of 50/50 or 75/25 and acid (A) or ester (E) end-capping in *N*-methyl-2-pyrrolidone at a polymer/solvent ratio of 20/80% (*w/w*). Mean *in vitro* drug release in 0.05 M phosphate buffer pH 7.4 with 1% (*w/v*) sodium lauryl sulphate was 37.3, 47.1, 53.3, and 62.3% within 28 days for ISGs containing PLGA5050A, PDLLA, PLGA7525A, and PLGA7525E, respectively. The data suggested that drug release was primarily controlled by precipitated drug redissolving, rather than polymer erosion. *In vivo* pharmacokinetic profiles after subcutaneous injections in rats were comparable for all ISGs (mean half-lives ($t_{1/2}$) ranged from 1411 to 1695 h) and indicated a sustained drug release when compared to a solution of bedaquiline fumarate salt in polyethylene glycol 400/water 50/50% (*v/v*) (mean $t_{1/2}$ of 895 h). In conclusion, PLGA or PDLLA-based ISGs have shown potential for parenteral sustained delivery of bedaquiline, suggesting further preclinical and clinical studies. From a formulation point of view, this case example highlights the importance of the interplay between drug solubility in biological media and dissolution of drug precipitates, which, in addition to the incorporation of diffusion controlling polymers, governs the release of the active drug.

Linking *In Vitro* Intrinsic Dissolution Rate and Thermodynamic Solubility with Pharmacokinetic Profiles of Bedaquiline Long-Acting Aqueous Microsuspensions in Rats. Vy Nguyen, Jan Bevernage, Nicolas Darville, Christophe Tistaert, Jan Van Bocxlaer, Stefaan Rossenu, and An Vermeulen. *Molecular Pharmaceutics* 2021 18 (3), 952-965. DOI: [10.1021/acs.molpharmaceut.0c00948](https://doi.org/10.1021/acs.molpharmaceut.0c00948)

Pharmacokinetic (PK) profiles of a range of bedaquiline (BDQ) long-acting injectable (LAI) microsuspensions in rats after parenteral (*i.e.*, intramuscular and subcutaneous)

administration were correlated with the *in vitro* intrinsic dissolution rate (IDR) and thermodynamic solubility of BDQ in media varying in surfactant type and concentration to better understand the impact of different nonionic surfactants on the *in vivo* performance of BDQ LAI microsuspensions. All LAI formulations had a similar particle size distribution. The investigated surfactants were d- α -tocopheryl polyethylene glycol 1000 succinate (TPGS), poloxamer 338, and poloxamer 188. Furthermore, the relevance of medium complexity by using a biorelevant setup to perform *in vitro* measurements was assessed by comparing IDR and thermodynamic solubility results obtained in biorelevant media and formulation vehicle containing different surfactants in varying concentrations. In the presence of a surfactant, both media could be applied to obtain *in vivo* representative dissolution and solubility data because the difference between the biorelevant medium and formulation vehicle was predominantly nonsignificant. Therefore, a more simplistic medium in the presence of a surfactant was preferred to obtain *in vitro* measurements to predict the *in vivo* PK performance of LAI aqueous suspensions. The type of surfactant influenced the PK profiles of BDQ microsuspensions in rats, which could be the result of a surfactant effect on the IDR and/or thermodynamic solubility of BDQ. Overall, two surfactant groups could be differentiated: TPGS and poloxamers. Most differences between the PK profiles (*i.e.*, maximum concentration observed, time of maximum concentration observed, and area under the curve) were observed during the first 21 days postdose, the time period during which particles in the aqueous suspension are expected to dissolve.

Kaushik A, Ammerman NC, Tasneen R, Lachau-Durand S, Andries K, Nueremberger E. Efficacy of long-acting bedaquiline regimens in a mouse model of tuberculosis preventive therapy. *Am. J. Respir. Crit. Care Med.* 2022;205:570–579.
<https://doi.org/10.1164/rccm.202012-4541OC>.

Rationale: Completion of preventive therapy is a major bottleneck in global tuberculosis control. Long-acting injectable drug formulations would shorten therapy administration and may thereby improve completion rates. Recently, a long-acting formulation of bedaquiline demonstrated antituberculosis activity for up to 12 weeks

after injection in a validated mouse model of preventive therapy.

Objectives: The objectives of this study were to 1) determine the total duration of activity after an injection of long-acting bedaquiline and 2) evaluate the activity of regimens comprised of long-acting bedaquiline plus short (2–4 wk) oral companion courses of bedaquiline, with or without rifapentine, using the validated mouse model of tuberculosis preventive therapy.

Methods: After the establishment of a stable *Mycobacterium tuberculosis* lung infection in bacillus Calmette-Guérin (BCG)-immunized BALB/c mice, treatment was initiated with 1 of 12 randomly assigned regimens. In addition to positive and negative controls, six regimens included one or two injections of long-acting bedaquiline (alone or with oral bedaquiline with or without rifapentine), and four comparator regimens consisted of oral agents only. Lung bacterial burden was measured monthly for up to 28 weeks.

Measurements and Main Results: One injection of long-acting bedaquiline at 160 mg/kg exerted antituberculosis activity for 12 weeks. Compared with the positive control (daily isoniazid-rifapentine for 4 wk), six regimens had equivalent bactericidal activity (including two all-oral comparator regimens), and two regimens had superior sterilizing activity: one injection with 2 weeks of oral bedaquiline and high-dose rifapentine; and two injections with 4 weeks of oral bedaquiline.

Conclusions: Long-acting injectable bedaquiline has significant potential for shortening tuberculosis preventive therapy.

Additional documents

No documents were uploaded

Useful links

There are no additional links

Access principles

Collaborate for development



Consider on a case by case basis, collaborating on developing long acting products with potential significant public health impact, especially for low- and middle-income countries (LMICs), utilising the referred to long-acting technology

Not provided

Share technical information for match-making assessment



Provide necessary technical information to a potential partner, under confidentiality agreement, to enable preliminary assessment of whether specific medicines of public health importance in LMICs might be compatible with the referred to long-acting technology to achieve a public health benefit

Not provided

Work with MPP to expand access in LMICs



In the event that a product using the referred to long-acting technology is successfully developed, the technology IP holder(s) will work with the Medicines Patent Pool towards putting in place the most appropriate strategy for timely and affordable access in low and middle-income countries, including through licensing

Not provided

Comment & Information

Not provided